A detailed history of Marshall Wace, LLP transactions in Repare Therapeutics Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 119,108 shares of RPTX stock, worth $370,425. This represents 0.0% of its overall portfolio holdings.

Number of Shares
119,108
Previous 82,590 44.22%
Holding current value
$370,425
Previous $272,000 50.37%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.75 - $3.99 $100,424 - $145,706
36,518 Added 44.22%
119,108 $409,000
Q2 2024

Aug 14, 2024

BUY
$3.02 - $4.7 $249,421 - $388,173
82,590 New
82,590 $272,000
Q4 2023

Feb 14, 2024

BUY
$3.22 - $11.79 $86,508 - $316,750
26,866 New
26,866 $196,000
Q4 2022

Feb 14, 2023

BUY
$12.5 - $18.13 $493,612 - $715,935
39,489 New
39,489 $580,000
Q2 2022

Aug 15, 2022

BUY
$8.45 - $14.84 $261,104 - $458,556
30,900 New
30,900 $433,000

Others Institutions Holding RPTX

About Repare Therapeutics Inc.


  • Ticker RPTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,937,800
  • Market Cap $130M
  • Description
  • Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that foc...
More about RPTX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.